<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04535752</url>
  </required_header>
  <id_info>
    <org_study_id>ANX009-NHV-01</org_study_id>
    <nct_id>NCT04535752</nct_id>
  </id_info>
  <brief_title>A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Subcutaneous ANX009 in Normal Healthy Volunteers (NHV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annexon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nucleus Network Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Annexon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmakokinetics and&#xD;
      pharmacodynamics of single and repeated doses of ANX009&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this first in human, phase 1, randomized, double-blind, placebo-controlled study, single&#xD;
      and multiple ascending doses of ANX009 or placebo will be administered to 48 healthy&#xD;
      subjects.&#xD;
&#xD;
      Single Ascending Dose (SAD): Each SAD subject will participate for approximately 4 weeks (3&#xD;
      nights in-clinic confinement).&#xD;
&#xD;
      Multiple Ascending Dose: Each MAD subject will participate for approximately 6 weeks (17&#xD;
      nights in-clinic confinement).&#xD;
&#xD;
      All subjects will be contacted (in clinic visit or phone call) 6 months after study&#xD;
      completion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2020</start_date>
  <completion_date type="Actual">June 26, 2021</completion_date>
  <primary_completion_date type="Actual">June 26, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Number of Participants Who Experienced Treatment-Emergent Adverse Events</measure>
    <time_frame>[Time Frame: Up to Day 29 for SAD; up to Day 43 for MAD]</time_frame>
    <description>Incidence and severity of treatment-emergent adverse events (AEs). AEs will be coded using MedDRA and severity of AEs will be graded using National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Total Amount of Complement Protein in Blood (CH50)</measure>
    <time_frame>Up to Week 6</time_frame>
    <description>Serum samples will be obtained to determine the amount of CH50. CH50 will be measured at a local laboratory. CH50 will be measured at a local laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Amount of C1 in Blood (C1q)</measure>
    <time_frame>Up to Week 6</time_frame>
    <description>Serum samples will be obtained to determine the amount of C1q. C1q will be measured using a validated enzyme-linked immunosorbent assay (ELISA) method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: Maximum Observed Serum Concentration (Cmax) of ANX009</measure>
    <time_frame>Pre-dose, immediately after dose, and 0.5, 1, 2, 4, 6, 8, 12, 24 hours post-dose on Day 1 (SAD and MAD) and 36, 48, and 72 hours post-dose Day 1 (SAD)</time_frame>
    <description>Single-dose Cmax (Day 1 in SAD and MAD) and multiple-dose Cmax (Day 14 in MAD) will be determined. Blood samples will be obtained, and serum concentrations determined using a validated ELISA method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: Time to Maximum Observed Serum Concentration (Tmax) of ANX009</measure>
    <time_frame>Pre-dose, immediately after dose, and 0.5, 1, 2, 4, 6, 8, 12, 24 hours post-dose on Day 1 (SAD and MAD) and 36, 48, and 72 hours post-dose Day 1 (SAD)</time_frame>
    <description>Tmax will be determined on Day 1 in SAD and MAD and on Day 14 in MAD. Blood samples will be obtained, and serum concentrations determined using a validated enzyme-linked immunosorbent assay (ELISA) method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: Area Under the ANX009 Serum Concentration-Time Curve to Last Sample (AUC 0-t) and extrapolated through infinity (AUC 0-inf)</measure>
    <time_frame>Pre-dose, immediately after dose, and 0.5, 1, 2, 4, 6, 8, 12, 24 hours post-dose on Day 1 (SAD and MAD) and 36, 48, and 72 hours post-dose Day 1 (SAD)</time_frame>
    <description>AUC 0-t will be determined on Day 1 in SAD and on Day 14 in MAD. Blood samples will be obtained, and serum concentrations determined using a validated enzyme-linked immunosorbent assay (ELISA) method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: Terminal Half-Life (t1/2) of ANX009</measure>
    <time_frame>Pre-dose, immediately after dose, and 0.5, 1, 2, 4, 6, 8, 12, 24 hours post-dose on Day 1 (SAD and MAD) and 36, 48, and 72 hours post-dose Day 1 (SAD)</time_frame>
    <description>Half-life will be determined on Day 1 in SAD and on Day 1 and Day 14 in MAD. Blood samples will be obtained, and serum concentrations determined using a validated enzyme-linked immunosorbent assay (ELISA) method</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Safety and Tolerability in Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ANX009, Single Ascending Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of ANX009 with a 7-day follow-up before escalation to the next dose level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Single Ascending Doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single doses of matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX009, Multiple Ascending Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANX009 once daily on Days 1-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Multiple doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo once daily on Days 1-14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANX009</intervention_name>
    <description>Single or multiple ascending dose</description>
    <arm_group_label>ANX009, Multiple Ascending Doses</arm_group_label>
    <arm_group_label>ANX009, Single Ascending Doses</arm_group_label>
    <other_name>009</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single or multiple ascending dose</description>
    <arm_group_label>Placebo, Multiple doses</arm_group_label>
    <arm_group_label>Placebo, Single Ascending Doses</arm_group_label>
    <other_name>matching placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male and non-pregnant, non-lactating female volunteers â‰¥18 to 59 years of age.&#xD;
&#xD;
          2. Females must be postmenopausal, surgically sterilized or willing and able to use&#xD;
             highly effective methods of contraception from screening through the final study&#xD;
             visit.&#xD;
&#xD;
          3. Males with a partner of childbearing potential must agree to use contraception from&#xD;
             Screening through the final study visit.&#xD;
&#xD;
          4. Documented history within 5 years of screening of previous vaccination against&#xD;
             encapsulated bacterial pathogens (MAD cohorts only).&#xD;
&#xD;
          5. Complete the full sequence of protocol-related doses, procedures and evaluations.&#xD;
&#xD;
          6. No alcohol and drugs of abuse at screening and baseline or through study completion.&#xD;
&#xD;
          7. Discontinue use of nutritional supplements and prescription and over-the-counter&#xD;
             medications (vitamins are allowed).&#xD;
&#xD;
          8. No new tattoos/piercings or elective surgery from screening through the End of Study&#xD;
             visit&#xD;
&#xD;
          9. Ability to understand and provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects must not meet any of the following criteria:&#xD;
&#xD;
          1. Clinically significant, ongoing illness or medical condition that would jeopardize the&#xD;
             safety of the subject, limit participation, or compromise the interpretation of the&#xD;
             safety data derived from the subject.&#xD;
&#xD;
          2. Clinically significant findings on the screening or Baseline ECG or physical&#xD;
             examination.&#xD;
&#xD;
          3. Clinically significant abnormalities on screening or Baseline laboratory assessments.&#xD;
&#xD;
          4. An ANA titer â‰¥ 1:160.&#xD;
&#xD;
          5. History of any autoimmune disease.&#xD;
&#xD;
          6. History of meningitis or septicemia.&#xD;
&#xD;
          7. Clinically significant infection that required medical intervention (not including&#xD;
             antibiotic prophylaxis) within 1 month prior to study drug dosing.&#xD;
&#xD;
          8. Known genetic deficiencies of the complement cascade system or immunodeficiency.&#xD;
&#xD;
          9. Treatment with an investigational therapeutic agent within 30 days prior to study drug&#xD;
             dosing.&#xD;
&#xD;
         10. Use of immunosuppressants or corticosteroids within 30 days prior to study drug&#xD;
             dosing.&#xD;
&#xD;
         11. Active alcohol abuse, drug abuse or substance abuse.&#xD;
&#xD;
         12. Hypersensitivity to any of the excipients in the ANX009 drug product or active&#xD;
             substance.&#xD;
&#xD;
         13. History of previous sensitivities or allergic or anaphylactic reactions to previous&#xD;
             medication injections.&#xD;
&#xD;
         14. Positive for HIV Ab, Hepatitis C Ab or Hepatitis B surface antigen (HBsAg) at&#xD;
             screening.&#xD;
&#xD;
         15. Body weight less than 50 kg or greater than 125 kg.&#xD;
&#xD;
         16. BMI less than 18 or greater than 30 (Asians greater than 27).&#xD;
&#xD;
         17. Current smoker defined as any occasional or daily smoking of tobacco products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Humphriss, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Annexon Director, Global Clinical Operations</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

